IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option

By Travere Therapeutics

Listeners can expect to learn about:

• The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression

• The current IgAN ... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option:

How many episodes does IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option have?

The podcast currently has 1 episodes available.

IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option episodes:

May 07, 2024 IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.
...more
17min

FAQs about IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option:

How many episodes does IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option have?

The podcast currently has 1 episodes available.